Research To Practice | Oncology Videos

Latest Episodes:

Prostate Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting Aug 12, 2026

Show notes

Featuring perspectives from Dr Wassim Abida, Dr Rahul Aggarwal, Dr Emmanuel S Antonarakis, Prof Karim Fizazi and Dr Rana R McKay, moderated by Dr McKay, including the following topics:

Introduction (0:00)
Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Antonarakis (2:42)
Current and Future Hormonal Treatment for Metastatic HSPC (mHSPC) — Dr Aggarwal (26:23)
Current and Future Role of Regimens Combining PARP Inhibitors and Androgen Receptor (AR) Pathway Inhibitors in Metastatic Prostate Cancer — Dr Abida (53:01)
Emerging Role of AKT Inhibition for Patients with mHSPC — Prof Fizazi (1:17:22)
Current and Future Use of Radiopharmaceuticals in Metastatic Prostate Cancer — Dr McKay (1:39:37)

CME information and select publications

Myelofibrosis — Proceedings from a Webinar Held in Conjunction with the 2026 ASCO Annual Meeting Aug 11, 2026

Show notes

Featuring perspectives from Prof Claire Harrison and Dr Raajit K Rampal, including the following topics:

Introduction (0:00)
The Biopathophysiology of Myelofibrosis (MF) (2:19)
Current and Future Clinical Decision-Making in the Absence of Severe Cytopenias — Prof Harrison (7:49)
Managing MF for Patients with Anemia and Thrombocytopenia — Dr Rampal (35:00)
Upcoming at European Hematology Association (EHA) 2026 (49:22)

CME information and select publications

For Oncology Nurses: Targeting the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer — Proceedings from the 2026 Annual ONS Congress Aug 10, 2026

Show notes

Featuring perspectives from Dr Reva Basho, Ms Kelly Fischer, Ms Melissa Rikal and Dr Seth Wander, moderated by Dr Wander, including the following topics:

Introduction (00:00)
Identification of Appropriate Candidates for Agents Targeting the PI3K/AKT/mTOR Pathway (3:45)
Role of Inavolisib in HR-Positive Metastatic Breast Cancer (mBC) (13:00)
Strategies to Prevent and Manage Hyperglycemia (27:02)
Clinical Utility of Capivasertib for HR-Positive mBC (38:09)
Mitigation and Management of Gastrointestinal Adverse Events (51:05)
Management of Dermatologic Adverse Events (59:58)
Potential Role of Gedatolisib in the Management of HR-Positive mBC (1:08:42)
Monitoring and Management of Cytopenias (1:21:23)

CME information and select publications

Small Cell Lung Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting Aug 07, 2026

Show notes

Featuring perspectives from Dr Anne Chiang, Dr Apar Kishor Ganti, Dr Luis Paz-Ares and Dr Misty Dawn Shields, moderated by Dr Shields, including the following topics:

Introduction (0:00)
Optimizing First-Line and Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer (SCLC) — Dr Shields (2:17)
Management of Relapsed/Refractory SCLC — Dr Paz-Ares (33:24)
Ongoing Investigation and Potential Role of Antibody-Drug Conjugates in SCLC — Dr Chiang (1:02:28)
Management of Limited-Stage SCLC — Dr Ganti (1:31:54)

CME information and select publications

Gastroesophageal Cancers — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting Aug 06, 2026

Show notes

Featuring perspectives from Dr Yelena Y Janjigian, Dr Manish A Shah and Prof Eric Van Cutsem, moderated by Dr Janjigian, including the following topics:

Introduction (0:00)
HER2-Targeted Approaches in Advanced Gastroesophageal Cancers — Prof Van Cutsem (2:08)
Targeting CLDN18.2 in Advanced Gastroesophageal Cancers — Dr Shah (30:54)
Available Immunotherapeutic Strategies for Advanced Gastroesophageal Cancers — Dr Janjigian (1:01:39)

CME information and select publications

Chronic Lymphocytic Leukemia — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting Aug 05, 2026

Show notes

Featuring perspectives from Dr Jeremy S Abramson, Dr John N Allan, Dr Bita Fakhri, Dr Shuo Ma and Dr Mazyar Shadman, moderated by Dr Abramson, including the following topics:

Introduction (0:00)
Current and Future Role of Continuous Bruton Tyrosine Kinase (BTK) Inhibitor Therapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Fakhri (2:22)
Available and Emerging Approaches to Time-Limited Therapy for Treatment-Naïve CLL — Dr Allan (23:24)
Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Dr Ma (56:31)
Selection and Sequencing of Therapy for Relapsed/Refractory CLL — Dr Shadman (1:17:01)
Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL — Dr Abramson (1:38:24)

CME information and select publications

Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances in Therapeutic Targets Beyond EGFR Aug 04, 2026

Show notes

Featuring perspectives from Dr John V Heymach and Dr Maurice Pérol, including the following topics:

Introduction: Relative Impact of Targeted Treatment (0:00)
HER2 Alterations (8:04)
KRAS Mutations (24:25)
MET Overexpression (30:34)
ALK Fusions (32:34)
ROS1 Fusions (42:36)
RET Fusions (52:00)

CME information and select publications

Therapeutic Targets Beyond EGFR for Non-Small Cell Lung Cancer | Maurice Pérol, MD Aug 03, 2026

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Therapeutic Targets Beyond EGFR for Non-Small Cell Lung Cancer | Faculty Presentation 2: Therapeutic Approaches Targeting ALK, ROS1 and RET — Maurice Pérol, MD

CME information and select publications

Therapeutic Targets Beyond EGFR for Non-Small Cell Lung Cancer | John V Heymach, MD, PhD Aug 03, 2026

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Therapeutic Targets Beyond EGFR for Non-Small Cell Lung Cancer | Faculty Presentation 1: Therapeutic Approaches Targeting HER2, MET and KRAS G12C — John V Heymach, MD, PhD

CME information and select publications

For Oncology Nurses: Relapsed/Refractory Multiple Myeloma — Proceedings from the 2026 Annual ONS Congress Aug 03, 2026

Show notes

Featuring perspectives from Dr Beth Faiman, Dr Natalie S Callander, Dr Hans Lee and Dr Mary Steinbach, moderated by Dr Callander, including the following topics:

Introduction (00:00)
Role of Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory (R/R) MM (3:44)
Role of BCMA- and Non-BCMA-Targeted Bispecific Antibodies in R/R MM (27:00)
Utility of Belantamab Mafodotin in R/R MM (49:29)
Potential Role of Cereblon E3 Ligase Modulators in MM (1:07:01)

CME information and select publications

Our TOPPODCAST Picks

Follow Us

Stay Connected

Research To Practice | Oncology Videos

Related Podcasts

Links

Stay Connected